Y Intercept Hong Kong Ltd Buys 6,585 Shares of LivaNova PLC $LIVN

Y Intercept Hong Kong Ltd increased its stake in shares of LivaNova PLC (NASDAQ:LIVN) by 56.8% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 18,169 shares of the company’s stock after purchasing an additional 6,585 shares during the period. Y Intercept Hong Kong Ltd’s holdings in LivaNova were worth $1,155,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in LIVN. Millennium Management LLC grew its position in LivaNova by 17.3% in the 4th quarter. Millennium Management LLC now owns 3,484,082 shares of the company’s stock worth $214,376,000 after purchasing an additional 514,268 shares during the period. Wellington Management Group LLP lifted its holdings in shares of LivaNova by 83.5% during the 3rd quarter. Wellington Management Group LLP now owns 2,345,516 shares of the company’s stock valued at $122,858,000 after buying an additional 1,067,349 shares during the period. Vanguard Group Inc. boosted its stake in shares of LivaNova by 1.5% in the 4th quarter. Vanguard Group Inc. now owns 2,332,051 shares of the company’s stock worth $143,491,000 after buying an additional 34,812 shares during the last quarter. AQR Capital Management LLC grew its holdings in shares of LivaNova by 29.9% in the fourth quarter. AQR Capital Management LLC now owns 2,155,142 shares of the company’s stock worth $132,606,000 after acquiring an additional 496,165 shares during the period. Finally, Dimensional Fund Advisors LP grew its holdings in shares of LivaNova by 3.9% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,787,928 shares of the company’s stock worth $110,014,000 after acquiring an additional 66,755 shares during the period. Institutional investors own 97.64% of the company’s stock.

Analyst Upgrades and Downgrades

LIVN has been the subject of a number of research reports. Barclays upped their price objective on LivaNova from $73.00 to $76.00 and gave the company an “equal weight” rating in a research report on Thursday, May 7th. Weiss Ratings upgraded shares of LivaNova from a “sell (d+)” rating to a “hold (c)” rating in a research note on Thursday, May 7th. Freedom Capital raised shares of LivaNova to a “hold” rating in a report on Tuesday, June 30th. Mizuho upped their target price on shares of LivaNova from $85.00 to $90.00 and gave the company an “outperform” rating in a report on Thursday, May 7th. Finally, Robert W. Baird decreased their price target on shares of LivaNova from $78.00 to $76.00 and set an “outperform” rating on the stock in a research report on Thursday, May 7th. Six investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $80.75.

LivaNova Stock Performance

LIVN traded up $0.04 during midday trading on Friday, reaching $82.56. The company had a trading volume of 452,293 shares, compared to its average volume of 711,226. The business has a 50-day moving average of $76.00 and a two-hundred day moving average of $68.33. The company has a quick ratio of 1.11, a current ratio of 1.33 and a debt-to-equity ratio of 0.24. LivaNova PLC has a 1 year low of $41.01 and a 1 year high of $85.27. The company has a market cap of $4.54 billion, a P/E ratio of 42.34 and a beta of 0.86.

LivaNova (NASDAQ:LIVN) last posted its quarterly earnings data on Wednesday, May 6th. The company reported $0.98 earnings per share for the quarter, beating analysts’ consensus estimates of $0.85 by $0.13. The firm had revenue of $362.26 million for the quarter, compared to analysts’ expectations of $346.05 million. LivaNova had a return on equity of 16.48% and a net margin of 7.48%.The business’s quarterly revenue was up 14.3% on a year-over-year basis. During the same period in the previous year, the firm earned $0.88 EPS. LivaNova has set its FY 2026 guidance at 4.200-4.300 EPS. As a group, equities research analysts predict that LivaNova PLC will post 3.73 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other LivaNova news, Director Francesco Bianchi sold 1,800 shares of the company’s stock in a transaction that occurred on Tuesday, May 26th. The shares were sold at an average price of $75.75, for a total value of $136,350.00. Following the completion of the transaction, the director directly owned 7,228 shares in the company, valued at $547,521. This represents a 19.94% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.35% of the stock is owned by corporate insiders.

About LivaNova

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.